BioCentury
ARTICLE | Company News

Progenics, ITM Isotope Technologies Munich AG deal

September 30, 2013 7:00 AM UTC

Progenics granted ITM exclusive rights to manufacture and market Onalta edotreotide to treat cancer. ITM received worldwide rights except for Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and the United Arab Emirates. ITM said its ITG Isotope Technologies Garching GmbH affiliate will develop the yttrium-90 radiolabeled somatostatin peptide analog to treat metastatic neuroendocrine tumors (NETs), for which it is in Phase II testing. Onalta has also completed Phase II testing for advanced metastatic cancers expressing somatostatin receptors, pancreatic endocrine tumors and symptomatic malignant carcinoid tumors. Onalta has Orphan Drug designation in the EU to treat gastro-entero-pancreatic NETs. ITM declined to provide details, and Progenics could not be reached. ...